Australia Therapeutic Goods Administration granted provisional registration for Novavax COVID-19 vaccine
On Jan. 19, 2022, Novavaxa announced that Australia’s Therapeutic Goods Administration had granted approval for provisional registration of…
On Jan. 19, 2022, Novavaxa announced that Australia’s Therapeutic Goods Administration had granted approval for provisional registration of…
On Jan. 18, 2022, Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the…
On Jan. 14, 2022, the U.S. Department of Defense, in coordination with the U.S. Department of Health and…
On Jan. 12, 2022, Novavax and SK bioscience, a vaccine business subsidiary of Korea-based SK Group, announced that…
On Jan. 12, 2022, Pfizer announced positive top-line results from a Phase 3 study describing the safety and…
On Jan. 11, 2022, GlaxoSmithKline and Vir Biotechnology announced the US Government had purchased an additional 600,000 doses…
On Jan. 10, 2022, Novavax and Serum Institute of India announced a regulatory submission to the South African…
On Jan. 6, 2022, two new studies published in the journal Current Biology showed that environmental DNA (eDNA)…
On Jan. 4, 2022, Pfizer announced that the U.S. government had committed to purchasing an additional 10 million…
On Dec. 29, 2021, the Department of Defense (DoD), on behalf of and in coordination with the U.S….
On Dec. 28, 2021, Novavax and Serum Institute of India announced that the Drugs Controller General of India…
On Dec. 28, 2021, Pacific Biosciences announced that its new HiFiViral SARS-CoV-2 solution had successfully sequenced and captured…
On Dec. 27, 2021, Moderna announced that the Swiss Federal Government had exercised its option to purchase an…
On Dec. 27, 2021, Moderna announced a revised supply agreement with the government of South Korea for 20…
On Dec. 27, 2021, Sorrento Therapeutics announced that initial testing of COVISTIX on recombinant N proteins demonstrated its…
Our Heroes and Remembrance illustration has Maurice Ralph Hilleman and John Enders, pioneering developers of common vaccines, and…
On Dec. 24, 2021, Merck and Ridgeback Biotherapeutics announced that Japanï¾’s Ministry of Health, Labor and Welfare had…
On Dec. 23, 2021, Novavax and SK bioscience announced the expansion of the companies’ collaboration and license agreements…
On Dec. 23, 2021, Merck and Ridgeback Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) had…
On Dec. 23, 2021, Pfizer and BioNTech announced that they had submitted longer-term follow-up data from the companiesï¾’…
On Dec. 22, 2021, Gilead Sciences announced full results from a Phase 3 investigational study evaluating the efficacy…
On Dec. 22, 2021, Cocrystal Pharma announced that in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main…
On Dec. 22, 2021, Novavax announced initial data evaluating the immune response of its COVID-19 vaccine, NVX-CoV2373, against…
On Dec. 22, 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) had authorized the emergency…
On Dec. 21, 2021, Novavax announced that the first booster doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based…
On Dec. 21, 2021, the University of Oxford’s vaccine manufacturing research team published a pre-print paper demonstrating the…
On Dec. 20, 2021, Novavax announced that the World Health Organization (WHO) had granted a second Emergency Use…
On Dec. 20, 2021, Novavax announced that the European Commission (EC) had granted Novavax conditional marketing authorization (CMA)…
On Dec. 20, 2021, Pfizer and BioNTech announced an agreement had been reached with the European Commission (EC)…
On Dec. 20, 2021, Moderna announced preliminary neutralizing antibody data against the Omicron variant following the Company’s booster…